Esomeprazole

Esomeprazole (40mg enteric-coated) and Domperidone (30mg sustained-release) combines the pure S-enantiomer of omeprazole with an antiemetic prokinetic. Esomeprazole provides superior bioavailability and acid suppression compared to racemic omeprazole by undergoing lower first-pass hepatic metabolism via CYP2C19. Domperidone provides dopamine D2 receptor antagonism, enhancing lower esophageal sphincter tone and gastroduodenal transit. Indicated for erosive reflux esophagitis, GERD poorly responsive to standard acid suppression, and diabetic gastroparesis with nausea.

Esomeprazole (40mg enteric-coated) and Levosulpiride (75mg sustained-release) combines an S-isomer proton pump inhibitor with a central/peripheral prokinetic benzamide. Esomeprazole exerts long-lasting suppression of basal and meal-stimulated gastric acid secretion. Levosulpiride selectively blocks enteric D2 receptors and stimulates 5-HT4 receptors, dramatically improving gastric accommodation and antral motility. Indicated for severe GERD, refractory non-ulcer dyspepsia, and gastroparesis.

Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).

Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).

Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).

Esomeprazole Magnesium (40mg enteric-coated) and Itopride Hydrochloride (150mg sustained-release) combines an S-isomer PPI with a dual D2-antagonist/acetylcholinesterase-inhibiting prokinetic. Provides potent, round-the-clock acid suppression along with enhanced physiological acetylcholine-mediated peristalsis without cardiac HERG channel interactions. Indicated for erosive GERD and functional dyspepsia.

Naproxen (500mg delayed-release) and Esomeprazole (20mg gastro-resistant) Tablets combines a cardiovascular-safe NSAID with a potent proton pump inhibitor. Naproxen is associated with the lowest cardiovascular thrombotic risk among NSAIDs due to continuous 24-hour platelet COX-1 inhibition; esomeprazole elevates intragastric pH > 4, protecting gastric and duodenal mucosa from NSAID ulceration. Indicated for relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric ulcers.